Biomira, zum Glück redet keiner darüber - 500 Beiträge pro Seite

[IncreaseMaker]

Hi zusammen,
Glücklicherweise bin ich seit einiger Zeit bei einer
besonders gut performenden Aktie dabei,
Biomira 881836 [BIOM].
Nun weshalb wird nicht über sie gesprochen, aber
trotzdem jeden Tag ein Aufschlag von mehreren Prozent
herausgebildet?
Ich weiss es nicht, aber ich habe mir vorgenommen, mal
mit diesen ganzen Investoren über diese Aktie zu sprechen:
Soweit ich informiert bin ist BIOM in der Immunthreapie und
organischen Chemie tätig.
Das Phantasieprodukt ist THERATOPEÆ, welches sich aktuell in
Phase III befindet.
Das Ziel der Firma ist es ein Global Player in Sachen Krebs
Behandlung zu werden, ich finde die Chancen stehen nicht schlecht!
Was meint Ihr?
CU Maker

[Butler James]

Ich habe mit 4,5 gekauft und mit 13 verkauft! War ein gutes Geschäft!

Butler James

[Rubininvest]

BIOMIRA..

Gewinne jetzt mitnehmen und die "Results" von Phase 3 abwarten ,
das ist wohl die einzig plausible Strategie bei solchen high risks
denn sollte waehrend der Phase 3 nur eine schlechte News kommen oder
die Zulassung nicht klappen ,faellt das Ding ca.66% in wenigen Stunden,
so jedenfalls haben alle mir bekannten Biotechs (Latestageloser) auch
in etwa performed...

P.S. Wieso gibt`s zu BIOM keine Analystencoverages ,erzaehlt mir aber
nicht das Maerchen von der "unentdecken Perle" oder so`n Quatsch jaaaa
in der Tat ,das ist vollkommener Bloedsinn , es gibt bei 5000 Nasdaq-wer
erten keine Unentdeckten (frommer Wunsch) , meist ist da nur irgentwas
im Argen mit dem Wert....

[TheSimpson]

hier wenigstens eine news

Biomira Reports Progress at Biotechnology Industry Organization Conference
NEW YORK, Feb. 16 /CNW-PRN/ - Biomira Inc. (NASDAQ: BIOM - news; TSE: BRA - news) today presented at the Biotechnology Industry Organizations` second annual CEO & Investor Conference, highlighting the Company`s clinical and financing developments.

``We now have three major cancer vaccine product candidates plus an immune enhancer, Liposomal IL-2, in the clinic and up to U.S. $100 million in financing potentially available to push our products through to commercialization,`` commented President and CEO Alex McPherson, MD, PhD, who spoke at the conference today. ``Biomira is addressing the largest cancer markets with innovative product candidates. THERATOPE® vaccine for metastatic breast cancer is now in a pivotal Phase III trial, and BLP25 for lung cancer is in Phase II testing. Our patient-specific vaccine for lymphoma, co-developed with Biovector Therapeutics of Toulouse, France and the National Cancer Institute (NCI), entered NCI-sponsored Phase I trials in the first half of last year. We have a talented scientific staff and a strategically minded and dedicated management team that should be credited with our progress and success.``

At the conference, the Company reviewed its recently announced equity line financing and the increase in the maximum dollar amount of such financing from U.S. $36 million to a maximum of U.S. $100 million. The term of the equity line has also been increased from 30 months to 42 months. No additional shares of Biomira stock were needed to be reserved for issue, due to the increase in valuation and liquidity of the Company`s common stock. As Biomira continues negotiations with potential partners, the equity line gives the Company the ultimate flexibility of taking only the cash needed to develop its product portfolio.

Dr. McPherson also announced that the Company expects to complete enrolment of its Phase III THERATOPE® vaccine trial in the second half of 2000. The THERATOPE® vaccine Phase III trial will confirm whether the vaccine, Biomira`s lead product candidate, is effective in increasing patient survival as suggested by data from several Phase II trials. This trial is intended to include 900 evaluable patients with metastatic breast cancer. Enrolment has been increasing steadily in recent months, with more than 370 patients currently participating.

The multinational study officially began enrolling patients in late 1998 with most of the approximately 75 original sites in the U.S., the U.K., France, Germany, Belgium, Spain and Canada accruing patients in 1999. Biomira is in the process of adding approximately 30 new clinical sites to the trial, including sites in Australia, New Zealand and Ireland, plus additional sites in the U.S. and Europe. It is anticipated that there will shortly be more than 100 sites worldwide enrolling patients.

In the original 75 active sites, the trial accrued an average of 41 new patients per month over the last two months as the ramp-up continued. The current recruitment pace is expected to increase with the addition of the new study locations. In addition, in order to make the trial accessible to as many women as possible, the Company made amendments to its clinical trial protocol, allowing patients on hormonal therapy to participate and extending the window of opportunity during which patients may enroll. As well, the Company is attempting to ensure that patients on emerging first line chemotherapy treatments can be incorporated into the trial.

The Company is also aggressively pursuing public relations efforts and working with advocacy groups to make patients and their physicians aware of the opportunity to be involved in a clinical trial with this investigational product candidate. Investigators and patients have responded favorably to our efforts, and the Company feels confident that the trial accrual rate will increase even further with these new initiatives.

During today`s presentation, Dr. McPherson also described plans Biomira is aggressively pursuing for additional clinical trials with BLP25 vaccine. A Phase I study with BLP25 vaccine provided safety, immunological and survival data on 17 highly selected stage IIIb and stage IV non-small cell lung cancer patients randomized to be treated with either 20 mg or 200 mg doses of the vaccine. Preliminary immunology data demonstrated the induction of a cytotoxic T-lymphocyte (CTL) response capable of killing tumor cells in five out of the 12 evaluable non-small cell lung cancer patients from both arms of the study. BLP25 vaccine was found to be well tolerated and relatively non-toxic.

The median survival time of patients treated with the 20 mg dose regimen was 5.4 months from the time of entry to the study. The Kaplan-Meier projection of the median survival of the 200 mg dose regimen group is 14.7 months from the time of entry to the study, with three of the eight patients (37.5%) still alive.

Biomira is now conducting a series of Phase II trials to optimize the immune response against the BLP25 vaccine. The first stage of the Phase II trial was a study utilizing a dosage of 1000 mg of BLP25, which has been shown to induce a very strong CTL immune response in six out of eight patients to date. To the Company`s knowledge, this type of T-cell mediated cellular immune response has never been previously achieved in human carcinoma patients, nor was this level observed in the 20 mg or 200 mg patients in Phase I. Patients are being followed to determine if this increased T-cell response is reflected in an increased survival benefit. This type of immune response is strongly associated with tumour rejection in many pre-clinical animal models. Biomira is expecting to have survival data in the final quarter of 2000.

The Company is currently enrolling non-small cell lung cancer patients in a second stage of the Phase II trial to determine whether the vaccine`s immunogenicity can be further enhanced when combined with Liposomal Interleukin-2.

In a third research and development initiative, Biomira Inc. and its co-developer, Biovector Therapeutics of Toulouse France, are conducting an NCI-sponsored Phase I trial with an idiotypic vaccine for B-cell lymphoma. This novel treatment uses vaccines that incorporate each patient`s cancer antigen into a Liposomal Interleukin-2 formulation, and is specific for each individual patient. The vaccine is intended to trigger an immune attack directed specifically to the lymphoma cells. Early clinical data indicate that the autologous lymphoma vaccine is well tolerated and induces a potent anti-lymphoma immune response.

The Biotechnology Industry Organization is a Washington, D.C.-based organization that engages in lobbying, advocacy, communications and new business development related to the biotech industry. Established in 1993, today it includes more than 850 member companies. The goal of the CEO and Investor Conference is to provide a unique and neutral forum where CEOs from small, medium and large cap public companies and private firms planning to go public can interact with investors and other members of the financial community and the healthcare industry.

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. The commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer.

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of clinical trials, the efficacy of products or the availability of capital. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company`s expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

SOURCE: Biomira Inc.

[TheSimpson]

+ 13% in NY :-))))

[NoamX]

Soll Butler James doch rausgehen, ich habe für 3,50 gekauft,
und warte noch ab (heute 19) ;-)

NoamX

[TheSimpson]

zahlen zu biomira
Company Press Release
SOURCE: Biomira Inc.
Biomira Inc. Announces 4th Quarter and 1999 Results
EDMONTON, Alberta, March 3 /PRNewswire/ -- Biomira Inc. (Nasdaq: BIOM - news; Toronto: BRA. - news) today reported financial results for the fourth quarter and year ended December 31,1999. Results are reported in Canadian dollars with a December 31, 1999 rate of $1.00 Canadian equaling $0.68 U.S.

Financial results for the year ended December 31, 1999 reflect a consolidated net loss from operations of $31.4 million or $0.71 per share compared to $23.9 million or $0.54 per share, for the same period in 1998. The increased loss in 1999 is primarily attributable to an increase in expenditures related to the advancement of Biomira`s major product candidate, THERATOPE® vaccine for metastatic breast cancer, now being evaluated in a multinational Phase III trial.

Biomira`s cash position remains strong, with both $28.5 million in cash reserves as at December 31, 1999 and the ability under its previously announced equity line facility to access up to US $100 million over a 42 month period following the date of the initial drawdown. To date, the Company has drawn a total of approximately $23.5 million (US $16 million), under the equity line facility, which brings the current cash reserve figure after operating expenditures to approximately $46 million.

``We have made strategic investments in the interest of moving THERATOPE vaccine and our Phase III THERATOPE vaccine trial forward on schedule, while continuing to be secure in our cash position for the long term,`` commented Alex McPherson, MD, PhD, President and CEO.

Biomira last month announced that the Company is in the process of adding approximately 30 new clinical sites to its THERATOPE vaccine trial to support enrolment, which is anticipated to be completed in the second half of 2000. With more than 100 sites soon to be operational, patients and physicians have responded favorably and enrolment has been increasing steadily in recent months.

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. The Company is currently enrolling approximately 900 evaluable patients in a multinational Phase III trial with THERATOPE vaccine, as well as developing a portfolio of complementary vaccine candidates, including BLP25 for non-small cell lung cancer, now in Phase II trials. The commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. We are the Cancer Vaccine People(TM).


Biomira Inc.
SELECTED FINANCIAL DATA
($1.00 Cdn. - $0.68 US)

Three Months Ended Twelve Months Ended
December 31, 1999 December 31, 1999
(Unaudited) (Unaudited)
1999 1998 1999 1998
(Canadian dollars, in thousands, except per share amounts)
Revenue $641 $1,156 $4,798 $5,965
Research and Development expenses 9,209 6,899 28,933 20,223
Loss for the Period from Continuing
Operations (10,256) (7,189) (31,432) (22,482)
Discontinued Operations -- (174) -- (1,398)
Net loss for the Period (10,256) (7,363) (31,432) (23,880)
Loss per common share-Continuing
Operations $(0.23) $(0.16) $(0.71) $(0.51)
Loss per common share-
Discontinued Operations $ -- $ -- $ -- $(0.03)
Loss per common share $(0.23) $(0.16) $(0.71) $(0.54)
Weighted Average Number of Common
Shares Outstanding (millions) 44.4 44.3 44.4 44.3


Balance Sheet Data December 31, 1999 December 31, 1998
(Unaudited) (Audited)
(Canadian dollars, in thousands, except number of shares)

Cash and Short-Term Investments $28,545 $58,520
Working Capital 26,283 56,913
Total Assets 32,985 63,486
Total Shareholders` Equity $28,630 $58,742
Common Shares Issued 44,661,131 44,364,618


This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of clinical trials, availability or adequacy of financing or the efficacy of products. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company`s expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

SOURCE: Biomira Inc.



--------------------------------------------------------------------------------
More Quotes and News: Biomira Inc (NasdaqNM:BIOM - news; Toronto:BRA.TO - news)
Related News Categories: biotech, earnings, medical/pharmaceutical

[Butler James]

Hi NaomX

Ich habe nur die Hälfte mit 13 verkauft!

Die andere vor kurzem mit 19.75!

Bei solchen Aktien muß man immer vorsichtig sein, es ist ja schließlich mein Geld! Und ich habe noch immer lieber einen Gewinn als einen Verlust!

Also viel Glück noch NaomX

Butler James

[bambil]

haloo allesamt

Biomira wird langsam aber stetig steigen...
Nach dem letzten kursflug nach oben und nach unten müsste es langsam wieder gen norden gehn.


mfg
bambil
ich bleib investiert

[TheSimpson]

eine news...

SOURCE: Biomira Inc.
Biomira Presents New Data at Biotechnology Industry Organization Meeting
Findings Show BLP25 Vaccine Stimulates Potent T-cell Responses in a High Proportion of Cancer Patients
BOSTON, March 27 /CNW-PRN/ - Biomira Inc. (Nasdaq: BIOM - news; TSE: BRA - news) today presented data at a meeting of the Biotechnology Industry Organization in Boston suggesting that its synthetic cancer vaccine, BLP25 vaccine, is capable of inducing a potent immune response against MUC-1 cancer associated antigen in a high proportion of cancer patients. MUC-1 cancer associated antigen is expressed on over 90 percent of common human cancers.

``Most peptide antigens stimulate the T-cell response in only a subset (usually a minority) of people. The ability to induce a strong T-cell response against a peptide antigen in such a high proportion of patients is an unusual phenomenon, and we are extremely excited that BLP25 vaccine has performed so well,`` said Michael Longenecker, PhD, Senior Vice President, Research and Development.

Data from two BLP25 vaccine recent studies support these conclusions. One was an in vitro study using T-cells from normal human donors and a second was from a Phase II clinical trial. In the in vitro study, dendritic cells, the most potent antigen presenting cells, were incubated with BLP25 vaccine before incubation with donors` T-cells. Twelve out of 14 (86 percent) of normal donors were able to generate a strong primary T-cell response against MUC-1.

In the clinical trial, a Phase II study with BLP25 vaccine to determine whether a higher dose (1,000 mg) and more frequent administration would lead to an increased immune response, six out of eight evaluable non-small cell lung cancer patients experienced significant T-cell proliferative responses against the target antigen.

``Biomira has always stated that the MUC-1 cancer mucin, upon which our BLP25 vaccine is based, is expressed by over 90 percent of common cancers. We were extremely pleased to find that a high proportion of cancer patients are also responsive to our vaccine expressing MUC-1 peptide. This means that a successful BLP25 vaccine has the possibility of targeting a very large number of patients with common cancers - a potentially huge market,`` said Alex McPherson, MD, PhD, President and CEO of Biomira.

A second Phase II study with BLP25 vaccine is currently under way to examine the efficacy of adding the immune enhancer interleukin-2 to Biomira`s vaccine formulation, while preserving a satisfactory safety profile.

The Biotechnology Industry Organization is a Washington, D.C.-based organization that engages in lobbying, advocacy, communications and new business development related to the biotech industry. Established in 1993, today it includes more than 850 member companies.

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. The commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. We are The Cancer Vaccine People(TM).

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of clinical trials, the efficacy of products or the availability of capital. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company`s expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

SOURCE: Biomira Inc.

[TheSimpson]

und noch eine .....

SOURCE: Biomira Inc.
Biomira Presents at American Chemical Society National Meeting

SAN FRANCISCO, CA, March 28 /CNW-PRN/ - Biomira Inc. (Nasdaq: BIOM - news; TSE:
BRA) presented today at the American Chemical Society`s 219th National Meeting
and Exposition in San Francisco. Dr. Grant MacLean, Biomira`s Vice President
of Clinical and Regulatory Affairs, updated the Company`s clinical programs
and discussed the future of cancer vaccine development.
``Biomira has been one of the driving forces in the emergence of cancer
vaccines as the next generation of cancer treatments since our clinical
program began a decade ago,`` commented Dr. MacLean. ``We now have three
exciting product candidates in clinical trials: THERATOPE® vaccine for
metastatic breast cancer in a Phase III trial, which is enrolling patients in
over 100 sites in 10 countries world-wide; BLP25 vaccine, which is being
tested in two parallel Phase II trials; and our liposomal patient-specific
vaccine, co-developed with Biovector Therapeutics of Toulouse, France, which
is being evaluated at the National Cancer Institute in patients with B-cell
lymphoma. Further development of our cancer vaccines could include testing
products in earlier stage disease, identifying new antigens, testing vaccines
in other indications and enhancing the effect of vaccines by the concomitant
or associated use of appropriate cytokines.``
The Company`s lead product in development, THERATOPE® vaccine, is
currently being tested in a multinational trial involving up to 900 evaluable
patients. Biomira expects to complete enrollment in the last quarter of 2000.
In Phase II studies, BLP25 vaccine has induced potent T-cell mediated immune
responses in patients with lung cancer which express MUC-1.
Biomira has found that the MUC-1 cancer mucin, upon which our BLP25
vaccine is based, is expressed by over 90 percent of common cancers. Also, a
high proportion of patients are responsive to vaccines containing the MUC-1
mucin.
With close to 9,000 members in attendance, the 219th National Meeting of
the American Chemical Society is believed to be the largest in history, in
terms of attendance and number of presentations. The theme of this meeting is
``What Chemistry May Bring to the 21st Century``. Approximately 9,000 papers
are being presented highlighting the latest scientific research in medicine,
health, the environment and food.
``We are honored to be part of such a prestigious meeting and have the
opportunity to present, to such a diverse audience, our cutting edge
technology,`` said Alex McPherson, MD, PhD, President and CEO of Biomira.
The American Chemical Society, with over 160,000 members is a
self-governed individual membership organization that seeks to foster
communication and understanding between members of the chemical industry, the
government and the public to enhance the quality of scientific research,
support economic progress and ensure public health and safety.
Biomira is a biotechnology company specializing in the development of
innovative therapeutic approaches to cancer management. The commitment to the
treatment of cancer currently focuses on the development of synthetic vaccines
and novel strategies for cancer immunotherapy. We are The Cancer Vaccine
People(TM).

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements, including those predicting the timing of clinical
trials, the efficacy of products or the availability of capital. Although the
Company believes that the forward-looking statements contained herein are
reasonable, it can give no assurance that the Company`s expectations are
correct. All forward-looking statements are expressly qualified in their
entirety by this cautionary statement.

SOURCE: Biomira Inc.